Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filgotinib - Galapagos/Gilead Sciences

Drug Profile

Filgotinib - Galapagos/Gilead Sciences

Alternative Names: Filgotinib hydrochloride; G-146034; G-146034-101; GLPG-0634; GS-6034

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Gilead Sciences
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antirheumatics; Cyclopropanes; Pyridines; Skin disorder therapies; Small molecules; Thiamorpholines; Triazoles; Urologics
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Phase III Crohn's disease; Psoriatic arthritis; Ulcerative colitis
  • Phase II Ankylosing spondylitis; Cutaneous lupus erythematosus; Lupus nephritis; Sjogren's syndrome; Uveitis

Most Recent Events

  • 13 Nov 2019 Phase-III clinical trials in Psoriatic arthritis in USA (PO, Tablet) (NCT04115839)
  • 09 Nov 2019 Pooled safety data from the phase III FINCH programme trial in Rheumatoid arthritis presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting (ACR/ARP-2019)
  • 09 Nov 2019 Safety and efficacy data from the phase IIb DARWIN 3 trial in Rheumatoid arthritis presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting (ACR/ARP-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top